# Oncocyte acquires Chronix Biomedical for blood-based cancer monitoring technology

Oncocyte Corporation entered a definitive agreement to acquire Chronix Biomedical, including its intellectual property and technology for blood-based immune therapy monitoring and transplant rejection testing. The deal includes Chronix's development team and lab operations in Germany.

- Type: Acquisition
- Announced: 2021-02-02
- Where: Germany, Germany
- Status: announced
- Products: TheraSure-CNI Monitor, blood-based immune therapy monitoring test, organ transplant technology
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Oncocyte Corporation](https://endata.com/companies/52990.md) (acquirer)
- [Chronix Biomedical](https://endata.com/companies/52991.md) (target)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2021/02/02/2168130/0/en/oncocyte-announces-definitive-agreement-to-acquire-chronix-biomedical-inc.html), 2021-02-02: "Oncocyte will acquire the intellectual property (IP) and technology for Chronix's TheraSure-CNI Monitor, a patented, blood-based test for immune-therapy monitoring, as well as the IP for Chronix's organ transplant technology."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.